Yekaterina Khronusova, MD
Hospitalist · Las Vegas, NVNPI 1316949928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Merz North America, Inc. accounts for 94.7% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $122.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$349
- Teva Pharmaceuticals USA, Inc.$19
Across 155 payments — averaging $2556.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$352K
- GSK$38K
- AstraZeneca$6K
What the payments were for
- Food & beverage$368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 2 | $349 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$349
How this compares
$368 in reported general payments places this provider in the 75th percentile of 191 hospitalist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Minoxidil | 12 | $78 |
| ClopidogrelClopidogrel Bisulfate | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Las Vegas
- Manlin JinLas Vegas$2K
- Sean KumarLas Vegas$2K
- Caitlyn WaltersLas Vegas$2K
- Swati WadhwaniLas Vegas$2K
- Kamran KhanLas Vegas$2K
- Haitham ElconsulLas Vegas$2K
- Jay KumarLas Vegas$2K
- Sikisam MagoyagLas Vegas$1K
- Vishal ShahLas Vegas$840
- Andrew JonesLas Vegas$816
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.